Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MRNA Moderna	$25.90 +2.0%	$26.28	$23.15 ▼ $138.07	$10.02B	1.86	8.50 million shs	13.76 million shs
NVAX Novavax	$6.41 +1.7%	$6.74	$5.01 ▼ $17.81	$1.04B	2.81	6.39 million shs	4.82 million shs
PFE Pfizer	$23.97 +0.4%	$23.26	$20.92 ▼ $31.54	$136.27B	0.57	41.34 million shs	62.63 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MRNA Moderna	0.00%	-2.89%	-1.37%	-24.20%	-80.58%
NVAX Novavax	0.00%	-7.64%	-11.59%	-16.64%	-54.21%
PFE Pfizer	0.00%	-2.22%	+2.72%	-8.28%	-13.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
MRNA Moderna	4.4624 of 5 stars	4.0	2.0	0.0	4.6	1.5	2.5	1.3
NVAX Novavax	4.3897 of 5 stars	3.1	2.0	0.0	4.7	1.3	0.8	3.1
PFE Pfizer	4.8576 of 5 stars	2.3	4.0	4.2	4.3	2.3	1.7	3.1

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MRNA Moderna	2.04	Hold	$46.61	79.97% Upside
NVAX Novavax	2.29	Hold	$17.00	165.21% Upside
PFE Pfizer	2.53	Moderate Buy	$29.17	21.69% Upside

Current Analyst Ratings Breakdown

Latest NVAX, PFE, and MRNA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	NVAX Novavax	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$6.00
6/2/2025	MRNA Moderna	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
5/22/2025	MRNA Moderna	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$33.00 ➝ $26.00
5/19/2025	NVAX Novavax	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/9/2025	NVAX Novavax	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$9.00 ➝ $7.00
5/2/2025	MRNA Moderna	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$78.00 ➝ $70.00
5/2/2025	MRNA Moderna	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$45.00 ➝ $40.00
5/2/2025	MRNA Moderna	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform ➝ Sector Perform	$32.00 ➝ $28.00
5/2/2025	MRNA Moderna	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	In-Line ➝ In-Line	$50.00 ➝ $32.00
4/30/2025	PFE Pfizer	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$24.00 ➝ $25.00
4/22/2025	PFE Pfizer	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Neutral	$24.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MRNA Moderna	$3.24B	3.10	N/A	N/A	$28.33 per share	0.91
NVAX Novavax	$682.16M	1.52	N/A	N/A	($3.89) per share	-1.65
PFE Pfizer	$63.63B	2.14	$4.37 per share	5.49	$15.62 per share	1.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MRNA Moderna	-$3.56B	-$8.73	N/A	N/A	N/A	-105.67%	-28.69%	-21.94%	7/30/2025 (Estimated)
NVAX Novavax	-$187.50M	$2.65	2.42	80.13	0.07	38.14%	-115.51%	29.99%	8/14/2025 (Estimated)
PFE Pfizer	$8.03B	$1.38	17.37	7.91	0.87	12.62%	20.33%	8.53%	7/29/2025 (Estimated)

Latest NVAX, PFE, and MRNA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	NVAX Novavax	$0.71	$2.93	+$2.22	$2.93	$204.08 million	$666.66 million
5/1/2025	Q1 2025	MRNA Moderna	-$2.92	-$2.52	+$0.40	-$2.52	$130.35 million	$108.00 million
4/29/2025	Q1 2025	PFE Pfizer	$0.67	$0.92	+$0.25	$0.52	$14.43 billion	$13.72 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
MRNA Moderna	N/A	N/A	N/A	N/A	N/A
NVAX Novavax	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	7.18%	N/A	124.64%	16 Years

Latest NVAX, PFE, and MRNA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/23/2025	PFE Pfizer	quarterly	$0.43	7.69%	5/9/2025	5/9/2025	6/13/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MRNA Moderna	N/A	4.22	4.14
NVAX Novavax	N/A	2.06	2.03
PFE Pfizer	0.64	1.26	0.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MRNA Moderna	75.33%
NVAX Novavax	53.04%
PFE Pfizer	68.36%

Insider Ownership

Company	Insider Ownership
MRNA Moderna	11.00%
NVAX Novavax	1.00%
PFE Pfizer	0.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MRNA Moderna	5,800	386.74 million	344.20 million	Optionable
NVAX Novavax	1,990	161.97 million	160.35 million	Optionable
PFE Pfizer	81,000	5.69 billion	5.68 billion	Optionable

NVAX, PFE, and MRNA Headlines

Recent News About These Companies

Cambridge Investment Research Advisors Inc. Acquires 64,277 Shares of Pfizer Inc. (NYSE:PFE)

June 22 at 7:25 AM | marketbeat.com

Kentucky Retirement Systems Insurance Trust Fund Has $4.18 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

June 22 at 6:20 AM | marketbeat.com

Heartland Bank & Trust Co Buys New Shares in Pfizer Inc. (NYSE:PFE)

June 22 at 5:30 AM | marketbeat.com

Matrix Asset Advisors Inc. NY Grows Stock Holdings in Pfizer Inc. (NYSE:PFE)

June 22 at 5:13 AM | marketbeat.com

Center For Asset Management LLC Reduces Stake in Pfizer Inc. (NYSE:PFE)

June 21 at 7:21 AM | marketbeat.com

Woodmont Investment Counsel LLC Acquires 16,987 Shares of Pfizer Inc. (NYSE:PFE)

June 21 at 7:00 AM | marketbeat.com

Monte Financial Group LLC Purchases 43,740 Shares of Pfizer Inc. (NYSE:PFE)

June 21 at 6:50 AM | marketbeat.com

World Equity Group Inc. Sells 38,707 Shares of Pfizer Inc. (NYSE:PFE)

June 21 at 6:25 AM | marketbeat.com

PFG Investments LLC Grows Position in Pfizer Inc. (NYSE:PFE)

June 21 at 5:50 AM | marketbeat.com

Advocate Group LLC Increases Stock Position in Pfizer Inc. (NYSE:PFE)

June 21 at 5:50 AM | marketbeat.com

Advisor Resource Council Invests $1.55 Million in Pfizer Inc. (NYSE:PFE)

June 21 at 5:21 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Position Reduced by United Advisor Group LLC

June 21 at 4:39 AM | marketbeat.com

Pfizer (NYSE:PFE) Joins FIBRE Consortium To Advance Fibrosis Treatment Through Innovative Imaging

June 20 at 2:24 PM | finance.yahoo.com

Pfizer vs BMY: Which Oncology Drugmaker Is a Better Choice for Now?

June 20 at 11:06 AM | zacks.com

June 20 at 10:00 AM | zacks.com

Will Pfizer Slash Its >7% Yielding Dividend? I Wouldn't Rule It Out

June 20 at 9:06 AM | seekingalpha.com

Private Wealth Partners LLC Raises Holdings in Pfizer Inc. (NYSE:PFE)

June 20 at 7:36 AM | marketbeat.com

Cantor Fitzgerald Investment Advisors L.P. Sells 14,500 Shares of Pfizer Inc. (NYSE:PFE)

June 20 at 7:26 AM | marketbeat.com

Good Steward Wealth Advisors LLC Acquires New Holdings in Pfizer Inc. (NYSE:PFE)

June 20 at 6:33 AM | marketbeat.com

Pfizer Inc. (NYSE:PFE) Shares Sold by Means Investment CO. Inc.

June 20 at 5:48 AM | marketbeat.com

Pfizer: An Offensive Play For A Bear Market

June 20 at 5:20 AM | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVAX, PFE, and MRNA Company Descriptions

Moderna NASDAQ:MRNA

$25.90 +0.50 (+1.97%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$25.93 +0.03 (+0.12%)

As of 06/20/2025 07:59 PM Eastern

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Novavax NASDAQ:NVAX

$6.41 +0.11 (+1.75%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$6.40 0.00 (-0.08%)

As of 06/20/2025 07:50 PM Eastern

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Pfizer NYSE:PFE

$23.97 +0.09 (+0.37%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$23.99 +0.02 (+0.09%)

As of 06/20/2025 07:59 PM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time